June 22 (Reuters) - Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, ...

The pharma giant will lose its patent protection on semaglutide, which is sold as Ozempic and Wegovy, in Canada after not ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...